Description: Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Home Page: www.tanvex.com
802 West Bay Road
George Town,
KY1-1205
Cayman Islands
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Yun Yen F.A.C.P., FACP, M.D., Ph.D. | Chairman, Pres & CEO |
| Mr. K. H. Lin | CFO , Corp. Controller & Accounting Officer |
| Val Chen | Director of Operation Management & Corp. Governance Officer |
| Mr. Zheng Xia | Chief Technology Officer |
| Linda Grillo | Director of Sales & Marketing |
| Lily Yuan | Site Controller of LJB |
| Dilip Joshi | VP of Operational Services - Tanvex US |
Exchange: TW
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.1163 |
| Price-to-Sales TTM: | 681.7752 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |